**Name of Journal: *World Journal of Clinical Urology***

**ESPS Manuscript NO: 26361**

**Manuscript Type: Review**

**Contemporary management of upper tract urothelial cell carcinoma**

Choi K *et al*. Urothelial cell carcinoma

**Kellen Choi, Ryan McCafferty, Samuel Deem**

**Kellen Choi, Samuel Deem,** Department of Urology, Charleston Area Medical Center, Charleston, WV 25304, United States

**Ryan McCafferty,** Department of Anesthesiology PGY-1, Larkin Community Hospital, South Miami, FL 33143, United States

**Author contributions:** Choi K wrote the paper; McCafferty R and Deem S performed literature review.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Kellen Choi, DO,** Department of Urology, Charleston Area Medical Center, 3200 MacCorkle Ave, S.E., Charleston, WV 25304, United States. bchoi@alum.unthsc.edu

**Telephone:** +1-304-3885280

**Fax: +**1-304-3885291

**Received:** April 5, 2016

**Peer-review started:** April 8, 2016

**First decision:** July 14, 2016

**Revised:** November 7, 2016

**Accepted:** December 27, 2016

**Article in press:**

**Published online:**

**Abstract**

Upper tract urothelial cell carcinoma (UTUCC), formerly known as transitional cell carcinoma of the upper urinary tract, is a rare oncologic disease in Western countries. Thus its disease process and its management are not as well defined as other urologic cancers. We are reviewing the current evidence based literature available to develop a plan for the treatment of UTUCC. A PubMed search was completed using the key words ‘upper tract urothelial cell carcinoma,’ ‘epidemiology,’ ‘risk factor’, ‘treatment,’ and ‘prognosis.’ Six hundred fifty two articles were found. We narrowed our search to articles published between January 2004 and June 2016 for a more contemporary review of the topic. Four hundred seventy articles were then available for review. Further detailed search was performed for relevance on the topic and hundred one articles were selected for the review. Many risk factors have been found to be associated with the development of UTUCC, including tobacco use. Patients are often asymptomatic and may only present with microscopic or gross hematuria. Tumor grade and stage are pivotal in determining the treatment options for UTUCC. Advancements in endoscopic techniques have aided in the diagnosis, grading and treatment of this disease. Treatment options include topical therapy, with combinations of methotrexate, vinblastine, doxorubicin and cisplatin or gemcitibine or cisplatin, endoscopic resection, segmental ureterectomy and ureteral implantation, and nephroureterectomy, including bladder cuff. Treatment recommendations depend on tumor grade and stage, renal function, tumor location and the patient’s prognosis. There are currently no tissue or blood-based biomarkers available to accurately monitor the disease. Further studies of gene expression and biomarkers may hopefully improve the management of this disease. Although rare in many countries, UTUCC is becoming more prevalent due to exposure to carcinogenic herbal remedies and other identifiable risk factors. Numerous treatment modalities, both surgical and chemotherapeutic, have been utilized to treat both low and high grade UTUCC tumors. Additional clinical trials are necessary to further develop methods for screening, treatment, and surveillance to improve management.

**Key words:** Urothelial cell carcinoma; Upper tract; Epidemiology; Risk factors; Diagnosis; Treatment; Prognosis

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** To review the current literature on upper tract urothelial cell carcinoma (UTUCC) and provide a contemporary management plan for treatment based on best available evidence. Large randomized controlled trials are lacking in UTUCC due to the fortunately rare occurrence of the disease. Treatment recommendations for the primary lesion, imaging, and follow-up in this review are based on the stage and grade of the tumor. Early diagnosis and aggressive treatment remains the mainstay of therapy for UTUCC.

Choi K, McCafferty R, Deem S. Contemporary management of upper tract urothelial cell carcinoma. *World J Clin Urol* 2016; In press

**INTRODUCTION**

Upper tract urothelial cell carcinoma (UTUCC) accounts for 95% of upper tract carcinoma, with the remaining types being squamous cell carcinoma and adenocarcinoma[1]. Although UTUCC is a rare disease in the West, with an incidence of approximately 40000 cases per year, the incidence has risen in recent years. It is more common and the incidence has risen quickly in Asian countries, especially Taiwan, along with the Balkan regions[2].

UTUCC shares a similar embryologic origin as the bladder, both being derived from the urothelium. But due to anatomic, biological, and molecular differences between upper tract urothelial carcinoma and bladder cancer, they have been referred to as “disparate twin” diseases[2,3]. Accurate local surgical staging and subsequent clinical staging (TNM) is important to help standardize treatment planning. Modern management of UTUCC includes chemotherapy, endoscopic procedures, and nephroureterectomy. We will review the epidemiology, risk factors, classification, diagnosis, staging and medical and surgical treatments of UTUCC.

**EPIDEMIOLOGY**

Upper tract urothelial cell cancer can be found with higher incidence in Balkan regions, and most recently in certain Asian countries especially in Taiwan[2,4,5].

Upper tract urothelial cell cancers are most commonly diagnosed later in life, mostly in the eighth decade[6]. However, it should also be considered in younger populations, especially in patients with exposure to aristolochic acid (AA) plants, which is commonly used for weight loss in Asian countries. It is a very uncommon disease, with an incidence of less than 1 case per 40000[2]. It makes up 5% of all urothelial tumors and 5% to 7% of all renal tumors[6]. Men are twice as likely to have UTUCC, compared to women[7]. Although low in incidence, UTUCC is very aggressive, as many patients are asymptomatic and tend to present later with advanced stage disease, often with metastasis. A thorough understanding of this disease is pivotal in successful diagnosis and treatment[8].

**RISK FACTORS**

The most well known risk factor for UTUCC is aristolochic acid plants, more commonly used in Balkan regions and in Asian countries, especially in Taiwan[4,9-12]. Balkan endemic nephropathy, associated with ingesting the arstolochic acid plants, can lead to renal failure and increased risk of UTUCC. In addition to increased exposure to aristolochic acid, Balkan populations are also known to have genetic and hereditary predisposition to UTUCC. Other risk factors are microsatellite instability and lynch syndrome type II[13-16]*.*

Other risk factors for UTUCC are similar to bladder urothelial cell carcinoma, with the most common risk factor being cigarette smoking[7,17,18]. Tobacco use is found to increase the relative risk exposure from 2.5 to 7[19]. Occupational exposures to chemicals such as petrochemical and plastic industries, ink solvents, coals, asphalt and aniline dye products are shared risk factors between UTUCC and bladder UCC[20,21]. Newly identified risk factors associated with UTUCC include inverted papilloma which are found in the bladder[22].

UTUCC can be associated with bladder urothelial cell carcinoma but occurs in less than 5%, although nearly 25% in patients with carcinoma in situ (CIS). Environmental exposures unique to upper tract tumors include Blackfoot disease, Artesian well water, weight-reducing pills, well water, arsenic, organic chlorides, and Ergot alkaloids[5,23]. Phenacetin-based analgesics and cyclophosphamide have also been found to be causative agents in UTUCC.

**PRESENTATION**

UTUCC has been associated with significant delays in presentation, as many cases are asymptomatic. However, these cancers tend to be very aggressive once they present. Typically, it presents with microscopic or gross hematuria. Flank pain can be present in up to 30% of patients. This is often attributed to urinary tract obstruction by the tumor.

The most common locations for this tumor are the renal pelvis and less often the ureter. Ureteral tumors are located most commonly in the lower ureter and least commonly in the upper ureter. Incidence based on location is as follows: distal ureter in 70%, mid ureter in 25% and then proximal ureter in 5%[24-26].

**DIAGNOSIS**

Contrasted imaging of the collecting systems and ureters with CT urogram or retropyelogram is necessary along with cystoscopy to diagnose UTUCC. UTUCC is most frequently identified as an obstruction or filling defect, often known as the ‘goblet sign’ when found in the ureter (Figure 1). CT urogram is the gold standard for both staging and diagnosis, with the sensitivity of 0.67-1 and specificity of 0.93[19,27-31]. If the patient has renal failure or another reason to avoid intravenous contrast, a retrograde pyelogram can be performed. Suspect UTUCC if a central renal tumor is seen, as the mass grows into the renal sinus (Figure 2).

Physicians must have a high index of suspicion for UTUCC when faced with a positive cytology despite having a negative cystoscopy, especially high grade UCC and CIS[32,33]. In this scenario, ureteral barbotage, also known as selective ureteral catherization is performed[34]. Ureteral washing has 80% sensitivity and ureteral brushing has 90% sensitivity. Of note, such selective collection of urine samples should occur prior to retrograde pyelography, as high-osmolar contrast agents may alter the cytologic features of the urine sample.

Once UTUCC is suspected, ureteropyeloscopy and biopsy is indicated[35-37]. Coupled with biopsy, ureteropyeloscopy is the method of choice for diagnosis of UTUCC[38-40]. However, due to the small size of the ureteral scopes, thin walled ureter and small biopsy forceps, staging is limited. Nevertheless, concordance between biopsy and final pathology is as high as 90% to 92%.

The TNM Staging System for UTUCC provided in Figure 3 and Table 1 defines the locations and extent of disease. The staging system begins at T0, which is no evidence of primary tumor and progresses to T4, where the tumor invades adjacent organs or through the kidney into the perinephric fat. Of note, tumor stage was identified as the most important determinant in predicting recurrence and survival. There for all efforts to obtain an accurately staged tissue is crucial[41].

Lymph node involvement for renal pelvis tumors may include renal hilar, paracaval, aortic, and retroperitoneal nodes. For ureteral lymph node involvement, renal hilar, iliac, paracaval, periureteral, and pelvic nodes are commonly involved.

**PROGNOSTIC FACTORS**

The most pivotal factors in determining prognosis are tumor stage and grade[42-46]. Invasion of the vascular, lymphatic, renal hilum and parenchyma, and perineural tissue surrounding the kidney has been shown to indicate more aggressive tumor behavior[47-52]. Multifocal disease, including areas such as the bladder, have been found to indicate a higher likelihood of recurrence and a worse overall prognosis[53]. Tumor necrosis greater than 10% is another independent risk factor indicating worse prognosis[54,55]. Age, gender and tumor location have been found to offer little information on disease course and predicting overall prognosis[56-61]. Numerous molecular markers including E-cadherin, Telomerase RNA component, hypoxia-inducible factor (HIF) 1-α, epithelial membrane protein 3, and C-erb-B2 have been investigated as possible diagnostic and prognostic tools[62-66]. More data is needed before applying the markers in a clinical setting.

**TREAMENT**

Stage and grade of the tumor is instrumental in deciding treatment plans. Nephroureteretomy (NU) with bladder cuff has been the gold standard, and remains the treatment of choice for high grade (TA/T1, HG or CIS), invasive, or multifocal tumors, along with regional lymph node dissection[42,67].

Segmental resection or distal ureterectomy may be indicated in select cases to preserve renal function[68-70]. Tumors located in the distal third of the ureter can utilize a Psoas Hitch[71,72] which was popularized by Turner-Warwick. This method is an effective means to bridge the resultant defect of the lower third of the ureter. However, a small contracted bladder is a contraindication due to insufficient bladder capacity.

Ureteral defects proximal to the pelvic brim require more than a Psoas hitch. A lengthy ureteral tumor or diseased ureter in a patient with a need to preserve renal function can utilize an ileal ureteral substitution. Relative contraindications for ileal ureteral substitution include renal insufficiency, bladder outlet obstruction, and inflammatory bowel disease.

Endoscopic resection or ablation can be considered in patients with a solitary kidney or poor surgical candidates, especially for low grade and low stage tumors[73-78]. Holmium or Nd: Yag may be used for tumor ablation, as well as ureteral resection via an ureteroscope (Figures 4 and 5)[79].

A percutaneous approach may be considered in large (>1.5cm) renal pelvis UCC that are grade 1 and possibly grade 2[80,81]. The advantage for the percutaneous approach is that after 2-3 wk and with a normal nephrogram, BCG or mitomycin may be administered into the collecting system through the nephrostomy tube, as opposed to retrograde administration via reflux up a ureteral stent which is more challenging[82-85]. The disadvantage for a percutaneous approach is that 1/3 will recur and it is more invasive than other treatment options.

There is a lack of prospective studies that use of chemotherapy, whether neoadjuvant or adjuvant, due to the low incidence of this disease. The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest the use of both with patient discretion (Table 2). For muscle invasive UCC, MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) or gemcitabine and cisplatin chemotherapy are both treatment options[85-91]. Of note, BCG and mitomycin treatment for upper tract UCC is extrapolated from bladder cancer and retrospective studies. There are currently no prospective studies showing improved survival and these are difficult to construct since it is such a rare disease. A role for BCG in the management of upper tract carcinoma in situ (CIS) has been demonstrated in retrospective studies, although a definitive efficacy of adjuvant topical therapy after endoscopic resection of Ta/T1 tumors has not yet been proven[84,92]. Of note, immunotherapy and chemotherapy in the upper tract has limitations due to difficulty delivering them to the system, unlike bladder instillations with such agents. Currently NCCN Guidelines® support using postsurgical intrapelvic chemotherapy or BCG for low grade UTUCC of the renal pelvis after endoscopic resection[91].

Chemotherapy for metastatic disease was studied using MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) in 184 patients from 1986 to 2004 at M.D. Anderson Center. Median recurrence-free survival was 2.4 years[75]. Patients with advanced disease should receive chemotherapy, preferably in a neoadjuvant setting. Enlarged lymph nodes should be biopsied prior to surgery, and if positive then intravenous chemotherapy should be administered, followed by surgery if no progression, as with bladder UCC.

Radiation plays a very small role in the treatment of UTUCC. Adjuvant radiotherapy may help limit local disease in a palliative setting. Although its role is limited, when combined with chemotherapy it may improve survival and disease-free survival[93,94].

**MANAGEMENT/SURVEILLANCE**

Management principles of UTUCC are similar to that of bladder cancer. Low grade/low stage tumors may recur, but have a low likelihood of progression and high grade/high stage tumors are more aggressive and have a higher chance to metastasize. The challenge is identifying tumors as Ta low grade and ruling out CIS and more aggressive tumors[95,96] as obtaining adequate tissue for diagnosis can be challenging. Surveillance after treatment of UTUCC comes with many options. Per the European Association of Urology guidelines, low grade/stage tumors follow up should include cystoscopy every 3 mo for 1-2 years with periodic urine cytology, then every 6 mo for 2 years[41]. If renal sparing surgery was performed, an ureteroscopy would also be required. If the tumor was high grade/stage the management would be similar to that of the low grade/stage. In addition you would recommend imaging of the pelvis and abdomen and a chest x-ray.

**CONCLUSION**

Upper tract urothelial cell carcinoma is a rare disease with an incidence of less than 40000 cases per year. The most common presenting symptoms of UTUCC include hematuria and ureteral obstructive symptoms such as flank pain. The work up would then include cystoscopy, urine cytology, BUN, Creatinine and a CT Urogram. Tumor stage and grade are the most important prognostic factors to help the physician determine the best treatment options for the patient. Nephroureterctomy continues to be the gold standard for treatment in high grade, high stage tumors. In patients with low grade/stage disease, an absent contralateral kidney, poor renal function, or bilateral disease, renal sparing therapies including endoscopic resection, intravesical therapy with BCG or mitomycin C, and ureteral resection with ureteroureterostomy or re-implantation should be considered as an option for treatment. With appropriate treatment, the 5 year recurrence free survival rate for low grade/stage disease can be as high as 92%. However if the disease is not caught early and the patient has high grade/stage disease the 5 year recurrence free survival can be as low as 5%-48%. Factors such as high pathological stage, lymph node metastasis and vascular invasion increase the risk of recurrence and lead to decreased overall survival. Due to the aggressive nature of this disease, and lack of large prospective studies on this topic, large multi-institutional clinical trials are necessary to further investigate options for diagnosis, treatment, and surveillance to help those diagnosed with UTUCC.


**ACKNOWLEDGEMENTS**

Special thanks to Mike Tran M.D. who drew illustrations for this topic.


**REFERENCES**

1. **Ploeg M**, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. *World J Urol* 2009; **27**: 289-293 [PMID: 19219610 DOI: 10.1007/s00345-009-0383-3]
2. **Matin SF**, Shariat SF, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP. Highlights from the first symposium on upper tract urothelial carcinoma. *Urol Oncol* 2014; **32**: 309-316 [PMID: 24397995 DOI: 10.1016/j.urolonc.2013.08.029]
3. **Wang Y**, Lang MR, Pin CL, Izawa JI. Comparison of the clonality of urothelial carcinoma developing in the upper urinary tract and those developing in the bladder. *Springerplus* 2013; **2**: 412 [PMID: 24024098 DOI: 10.1186/2193-1801-2-412]
4. **Chen CH**, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. Aristolochic acid-associated urothelial cancer in Taiwan. *Proc Natl Acad Sci U S A* 2012; **109**: 8241-8246 [PMID: 22493262 DOI: 10.1073/pnas.1119920109]
5. **Tan LB**, Chen KT, Guo HR. Clinical and epidemiological features of patients with genitourinary tract tumour in a blackfoot disease endemic area of Taiwan. *BJU Int* 2008; **102**: 48-54 [PMID: 18445081 DOI: 10.1111/j.1464-410X.2008.07565.x]
6. **Munoz JJ**, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. *J Urol* 2000; **164**: 1523-1525 [PMID: 11025695 DOI: 10.1016/S0022-5347(05)67019-X]
7. **Rink M**, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, Shariat SF. Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int* 2013; **112**: 623-637 [PMID: 23465088 DOI: 10.1111/bju.12014]
8. **Raman JD**, Shariat SF, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? *Urol Oncol* 2011; **29**: 716-723 [PMID: 20056458 DOI: 10.1016/j.urolonc.2009.11.007]
9. **Grollman AP**, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. *Proc Natl Acad Sci U S A* 2007; **104**: 12129-12134 [PMID: 17620607 DOI: 10.1073/pnas.0701248104]
10. **Arlt VM**, Stiborová M, vom Brocke J, Simões ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. *Carcinogenesis* 2007; **28**: 2253-2261 [PMID: 17434925]
11. **Laing C**, Hamour S, Sheaff M, Miller R, Woolfson R. Chinese herbal uropathy and nephropathy. *Lancet* 2006; **368**: 338 [PMID: 16860704]
12. **Lord GM**, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. *Lancet* 2001; **358**: 1515-1516 [PMID: 11705569 DOI: 10.1016/S0140-6736(01)06576-X]
13. **Roupret M**, Catto J, Coulet F, Azzouzi AR, Amira N, Karmouni T, Fromont G, Sibony M, Vallancien G, Gattegno B, Meuth M, Hamdy FC, Cussenot O. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. *J Med Genet* 2004; **41**: e91 [PMID: 15235034 DOI: 10.1136/jmg.2003.017871]
14. **Acher P**, Kiela G, Thomas K, O'Brien T. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. *BJU Int* 2010; **106**: 300-302 [PMID: 20553255 DOI: 10.1111/j.1464-410X.2010.09443.x]
15. **Rouprêt M**, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. *Eur Urol* 2008; **54**: 1226-1236 [PMID: 18715695 DOI: 10.1016/j.eururo.2008.08.008]
16. **Rouprêt M**, Cancel-Tassin G, Comperat E, Fromont G, Sibony M, Molinié V, Allory Y, Triau S, Champigneulle J, Gaffory C, Larré S, de la Taille A, Richard F, Hamdy FC, Cussenot O. Phenol sulfotransferase SULT1A1\*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 2007; **16**: 2500-2503 [PMID: 18006944]
17. **Pommer W**, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. *Nephrol Dial Transplant* 1999; **14**: 2892-2897 [PMID: 10570093 DOI: 10.1093/ndt/14.12.2892]
18. **Hagiwara M**, Kikuchi E, Tanaka N, Matsumoto K, Ide H, Miyajima A, Masuda T, Nakamura S, Oya M. Impact of smoking status on bladder tumor recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. *J Urol* 2013; **189**: 2062-2068 [PMID: 23328579 DOI: 10.1016/j.juro.2013.01.024]
19. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Bladder cancer. Version 2.2015. [accessed 2016 Feb 3]. Available from: URL: https: //www.nccn.org/professionals/physician\_gls/PDF/bladder.pdf
20. **Colin P**, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, Rouprêt M. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. *BJU Int* 2009; **104**: 1436-1440 [PMID: 19689473 DOI: 10.1111/j.1464-410X.2009.08838.x]
21. **Shinka T**, Miyai M, Sawada Y, Inagaki T, Okawa T. Factors affecting the occurrence of urothelial tumors in dye workers exposed to aromatic amines. *Int J Urol* 1995; **2**: 243-248 [PMID: 8564742 DOI: 10.1111/j.1442-2042.1995.tb00465.x]
22. **Furihata M**, Yamasaki I, Ohtsuki Y, Sonobe H, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N. p53 and human papillomavirus DNA in renal pelvic and ureteral carcinoma including dysplastic lesions. *Int J Cancer* 1995; **64**: 298-303 [PMID: 7591300]
23. **Palvio DH**, Andersen JC, Falk E. Transitional cell tumors of the renal pelvis and ureter associated with capillarosclerosis indicating analgesic abuse. *Cancer* 1987; **59**: 972-976 [PMID: 3815276 DOI: 10.1002/1097-0142(19870301)59: 5<972: : AID-CNCR2820590520>3.0.CO; 2-Y]
24. **Azémar MD**, Comperat E, Richard F, Cussenot O, Rouprêt M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. *Urol Oncol* 2011; **29**: 130-136 [PMID: 19762256 DOI: 10.1016/j.urolonc.2009.06.003]
25. **Raman JD**, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *Eur Urol* 2010; **57**: 1072-1079 [PMID: 19619934 DOI: 10.1016/j.eururo.2009.07.002]
26. **Melamed MR**, Reuter VE. Pathology and staging of urothelial tumors of the kidney and ureter. *Urol Clin North Am* 1993; **20**: 333-347 [PMID: 8388136]
27. **Dillman JR**, Caoili EM, Cohan RH, Ellis JH, Francis IR, Schipper MJ. Detection of upper tract urothelial neoplasms: sensitivity of axial, coronal reformatted, and curved-planar reformatted image-types utilizing 16-row multi-detector CT urography. *Abdom Imaging* 2008; **33**: 707-716 [PMID: 18253780 DOI: 10.1007/s00261-008-9360-3]
28. **Van Der Molen AJ**, Cowan NC, Mueller-Lisse UG, Nolte-Ernsting CC, Takahashi S, Cohan RH. CT urography: definition, indications and techniques. A guideline for clinical practice. *Eur Radiol* 2008; **18**: 4-17 [PMID: 17973110 DOI: 10.1007/s00330-007-0792-x]
29. **Wang LJ**, Wong YC, Chuang CK, Huang CC, Pang ST. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. *J Urol* 2009; **181**: 524-31; discussion 531 [PMID: 19100576]
30. **Wang LJ**, Wong YC, Huang CC, Wu CH, Hung SC, Chen HW. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. *J Urol* 2010; **183**: 48-55 [PMID: 19913253 DOI: 10.1016/j.juro.2009.08.144]
31. **Ng CK**, Shariat SF, Lucas SM, Bagrodia A, Lotan Y, Scherr DS, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? *Urol Oncol* 2011; **29**: 27-32 [PMID: 19117771 DOI: 10.1016/j.urolonc.2008.10.023]
32. **Zincke H**, Aguilo JJ, Farrow GM, Utz DC, Khan AU. Significance of urinary cytology in the early detection of transitional cell cancer of the upper urinary tract. *J Urol* 1976; **116**: 781-783 [PMID: 1003651]
33. **Highman WJ**. Transitional carcinoma of the upper urinary tract: a histological and cytopathological study. *J Clin Pathol* 1986; **39**: 297-305 [PMID: 3958217 DOI: 10.1136/jcp.39.3.297]
34. **Konety BR**, Metro MJ, Melham MF, Salup RR. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract. *Urol Int* 1999; **62**: 26-30 [PMID: 10436427 DOI: 10.1159/000030350]
35. **Abdel-Razzak OM**, Ehya H, Cubler-Goodman A, Bagley DH. Ureteroscopic biopsy in the upper urinary tract. *Urology* 1994; **44**: 451-457 [PMID: 8073566 DOI: 10.1016/S0090-4295(94)80116-9]
36. **Guarnizo E**, Pavlovich CP, Seiba M, Carlson DL, Vaughan ED, Sosa RE. Ureteroscopic biopsy of upper tract urothelial carcinoma: improved diagnostic accuracy and histopathological considerations using a multi-biopsy approach. *J Urol* 2000; **163**: 52-55 [PMID: 10604312]
37. **Keeley FX**, Kulp DA, Bibbo M, McCue PA, Bagley DH. Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma. *J Urol* 1997; **157**: 33-37 [PMID: 8976209 DOI: 10.1016/S0022-5347(01)65273-X]
38. **Brien JC**, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. *J Urol* 2010; **184**: 69-73 [PMID: 20478585]
39. **Lee KS**, Zeikus E, DeWolf WC, Rofsky NM, Pedrosa I. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. *Clin Radiol* 2010; **65**: 185-192 [PMID: 20152273 DOI: 10.1016/j.crad.2009.11.003]
40. **Ishikawa S**, Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Kubota K, Matsuno Y, Osawa T, Shinno Y, Kumagai A, Togashi M, Matsuda H, Mori T, Nonomura K. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. *J Urol* 2010; **184**: 883-887 [PMID: 20643446]
41. **Rouprêt M**, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. *Eur Urol* 2015; **68**: 868-879 [PMID: 26188393 DOI: 10.1016/j.eururo.2015.06.044]
42. **Margulis V**, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer* 2009; **115**: 1224-1233 [PMID: 19156917 DOI: 10.1002/cncr.24135]
43. **Sobin L**, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. Urological Tumours. Renal Pelvis and Ureter. 7th revised ed. Wiley-Blackwell, uicc 2009: 258-261
44. **Langner C**, Hutterer G, Chromecki T, Winkelmayer I, Rehak P, Zigeuner R. pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract. *Mod Pathol* 2006; **19**: 272-279 [PMID: 16424895]
45. **Lehmann J**, Suttmann H, Kovac I, Hack M, Kamradt J, Siemer S, Wullich B, Zwergel U, Stöckle M. Transitional cell carcinoma of the ureter: prognostic factors influencing progression and survival. *Eur Urol* 2007; **51**: 1281-1288 [PMID: 17125909 DOI: 10.1016/j.eururo.2006.11.021]
46. **Li CC**, Chang TH, Wu WJ, Ke HL, Huang SP, Tsai PC, Chang SJ, Shen JT, Chou YH, Huang CH. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. *Eur Urol* 2008; **54**: 1127-1134 [PMID: 18243511 DOI: 10.1016/j.eururo.2008.01.054]
47. **Kikuchi E**, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *J Clin Oncol* 2009; **27**: 612-618 [PMID: 19075275 DOI: 10.1200/JCO.2008.17.2361]
48. **Kim DS**, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. *Urology* 2010; **75**: 328-332 [PMID: 20018349 DOI: 10.1016/j.urology.2009.07.1350]
49. **Novara G**, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *Eur Urol* 2010; **57**: 1064-1071 [PMID: 20071073]
50. **Fujimoto H**, Tobisu K, Sakamoto M, Kamiya M, Kakizoe T. Intraductal tumor involvement and renal parenchymal invasion of transitional cell carcinoma in the renal pelvis. *J Urol* 1995; **153**: 57-60 [PMID: 7966791 DOI: 10.1097/00005392-199501000-00021]
51. **Davis BW**, Hough AJ, Gardner WA. Renal pelvic carcinoma: morphological correlates of metastatic behavior. *J Urol* 1987; **137**: 857-861 [PMID: 3573176]
52. **Rey A**, Lara PC, Redondo E, Valdés E, Apolinario R. Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. *Cancer* 1997; **79**: 2178-2185 [PMID: 9179065 DOI: 10.1002/(SICI)1097-0142(19970601)79: 11<2178: : AID-CNCR16>3.0.CO; 2-T]
53. **Corrado F**, Ferri C, Mannini D, Corrado G, Bertoni F, Bacchini P, Lelli G, Lieber MM, Song JM. Transitional cell carcinoma of the upper urinary tract: evaluation of prognostic factors by histopathology and flow cytometric analysis. *J Urol* 1991; **145**: 1159-1163 [PMID: 2033684]
54. **Zigeuner R**, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *Eur Urol* 2010; **57**: 575-581 [PMID: 19959276 DOI: 10.1016/j.eururo.2009.11.035]
55. **Seitz C**, Gupta A, Shariat SF, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *J Urol* 2010; **184**: 1895-1900 [PMID: 20846680 DOI: 10.1016/j.juro.2010.06.106]
56. **Fernández MI**, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology* 2009; **73**: 142-146 [PMID: 18845322 DOI: 10.1016/j.urology.2008.07.042]
57. **Lughezzani G**, Sun M, Perrotte P, Shariat SF, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. *Urology* 2010; **75**: 321-327 [PMID: 19962727 DOI: 10.1016/j.urology.2009.09.048]
58. **Shariat SF**, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol* 2011; **29**: 481-486 [PMID: 20886219 DOI: 10.1007/s00345-010-0594-7]
59. **Shariat SF**, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU Int* 2010; **105**: 1672-1677 [PMID: 19912201 DOI: 10.1111/j.1464-410X.2009.09072.x]
60. **Favaretto RL**, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. *Eur Urol* 2010; **58**: 574-580 [PMID: 20637540 DOI: 10.1016/j.eururo.2010.07.003]
61. **Isbarn H**, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *J Urol* 2009; **182**: 2177-2181 [PMID: 19758662 DOI: 10.1016/j.juro.2009.07.035]
62. **Eltz S**, Comperat E, Cussenot O, Rouprêt M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. *BJU Int* 2008; **102**: 532-535 [PMID: 18384628 DOI: 10.1111/j.1464-410X.2008.07659.x]
63. **Nakanishi K**, Kawai T, Suzuki M, Torikata C. Growth factors and oncogene products in transitional cell carcinoma. *Mod Pathol* 1996; **9**: 292-297 [PMID: 8685230]
64. **Nakanishi K**, Kawai T, Torikata C, Aurues T, Ikeda T. E-cadherin expression in upper-urinary-tract carcinoma. *Int J Cancer* 1997; **74**: 446-449 [PMID: 9291437 DOI: 10.1002/(SICI)1097-0215(19970822)74: 4<446: : AID-IJC15>3.0.CO; 2-7]
65. **Nakanishi K**, Kawai T, Hiroi S, Kumaki F, Torikata C, Aurues T, Ikeda T. Expression of telomerase mRNA component (hTR) in transitional cell carcinoma of the upper urinary tract. *Cancer* 1999; **86**: 2109-2116 [PMID: 10570439]
66. **Wang YW**, Li WM, Wu WJ, Chai CY, Liu HS, Lai MD, Chow NH. Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. *J Urol* 2014; **192**: 242-251 [PMID: 24333112 DOI: 10.1016/j.juro.2013.12.001]
67. **Remzi M**, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, Shariat SF. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int* 2009; **103**: 307-311 [PMID: 18990163 DOI: 10.1111/j.1464-410X.2008.08003.x]
68. **Lughezzani G**, Sun M, Perrotte P, Shariat SF, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. *Eur Urol* 2010; **57**: 956-962 [PMID: 20018438 DOI: 10.1016/j.eururo.2009.12.001]
69. **Phé V**, Cussenot O, Bitker MO, Rouprêt M. Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? *BJU Int* 2011; **108**: 130-138 [PMID: 21070580 DOI: 10.1111/j.1464-410X.2010.09835.x]
70. **Zigeuner R**, Pummer K. Urothelial carcinoma of the upper urinary tract: surgical approach and prognostic factors. *Eur Urol* 2008; **53**: 720-731 [PMID: 18207315 DOI: 10.1016/j.eururo.2008.01.006]
71. **Ahn M**, Loughlin KR. Psoas hitch ureteral reimplantation in adults--analysis of a modified technique and timing of repair. *Urology* 2001; **58**: 184-187 [PMID: 11489694 DOI: 10.1016/S0090-4295(01)01144-X]
72. **Manassero F**, Mogorovich A, Fiorini G, Di Paola G, De Maria M, Selli C. Ureteral reimplantation with psoas bladder hitch in adults: a contemporary series with long-term followup. *ScientificWorldJournal* 2012; **2012**: 379316 [PMID: 22919311]
73. **Chen GL**, Bagley DH. Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. *J Urol* 2000; **164**: 1173-1176 [PMID: 10992360 DOI: 10.1016/S0022-5347(05)67136-4]
74. **Gadzinski AJ**, Roberts WW, Faerber GJ, Wolf JS. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. *J Urol* 2010; **183**: 2148-2153 [PMID: 20399468 DOI: 10.1016/j.juro.2010.02.005]
75. **Brown GA**, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm? *BJU Int* 2006; **98**: 1176-1180 [PMID: 17125474 DOI: 10.1111/j.1464-410X.2006.06524.x]
76. **Bagley DH**, Grasso M. Ureteroscopic laser treatment of upper urinary tract neoplasms. *World J Urol* 2010; **28**: 143-149 [PMID: 20229233 DOI: 10.1007/s00345-010-0525-7]
77. **Rouprêt M**, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. *Urology* 2006; **67**: 1181-1187 [PMID: 16765178 DOI: 10.1016/j.urology.2005.12.034]
78. **Cornu JN**, Rouprêt M, Carpentier X, Geavlete B, de Medina SG, Cussenot O, Traxer O. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. *World J Urol* 2010; **28**: 151-156 [PMID: 20044752 DOI: 10.1007/s00345-009-0494-x]
79. **Abad PG**, Del Peso AC, Arjona MF. Holmium: YAG laser ablation of upper urinary tract transitional cell carcinoma with new Olympus digital flexible ureteroscope. *Urol Ann* 2013; **5**: 212-214 [PMID: 24049390 DOI: 10.4103/0974-7796.115748]
80. **Palou J**, Piovesan LF, Huguet J, Salvador J, Vicente J, Villavicencio H. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. *J Urol* 2004; **172**: 66-69 [PMID: 15201739 DOI: 10.1097/01.ju.0000132128.79974.db]
81. **Rouprêt M**, Traxer O, Tligui M, Conort P, Chartier-Kastler E, Richard F, Cussenot O. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. *Eur Urol* 2007; **51**: 709-13; discussion 714 [PMID: 16911852 DOI: 10.1016/j.eururo.2006.07.019]
82. **Irie A**, Iwamura M, Kadowaki K, Ohkawa A, Uchida T, Baba S. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. *Urology* 2002; **59**: 53-57 [PMID: 11796281 DOI: 10.1016/S0090-4295(01)01488-1]
83. **Nonomura N**, Ono Y, Nozawa M, Fukui T, Harada Y, Nishimura K, Takaha N, Takahara S, Okuyama A. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. *Eur Urol* 2000; **38**: 701-4; discussion 705 [PMID: 11111187 DOI: 10.1159/000020365]
84. **Thalmann GN**, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. *J Urol* 2002; **168**: 1381-1385 [PMID: 12352398]
85. **Audenet F**, Yates DR, Cussenot O, Rouprêt M. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). *Urol Oncol* 2013; **31**: 407-413 [PMID: 20884249 DOI: 10.1016/j.urolonc.2010.07.016]
86. **Hellenthal NJ**, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *J Urol* 2009; **182**: 900-906 [PMID: 19616245 DOI: 10.1016/j.juro.2009.05.011]
87. **Kaag MG**, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, Stifelman MD, Taneja SS, Huang WC. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. *Eur Urol* 2010; **58**: 581-587 [PMID: 20619530 DOI: 10.1016/j.eururo.2010.06.029]
88. **Lane BR**, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. *Cancer* 2010; **116**: 2967-2973 [PMID: 20564402 DOI: 10.1002/cncr.25043]
89. **Matin SF**, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. *Cancer* 2010; **116**: 3127-3134 [PMID: 20564621 DOI: 10.1002/cncr.25050]
90. **Kim TS**, Oh JH, Rhew HY. The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. *J Cancer* 2013; **4**: 686-690 [PMID: 24155781 DOI: 10.7150/jca.7326]
91. **Papatsoris AG**, Chrisofos M, Skolarikos A, Varkarakis I, Lekas A, Dellis A, Koritsiadis S, Deliveliotis C. Upper urinary tract transitional cell carcinoma. A 10-year experience. *Tumori* 2008; **94**: 75-78 [PMID: 18468339]
92. **Shapiro EY**, Lipsky MJ, Cha DY, McKiernan JM, Benson MC, Gupta M. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ. *J Endourol* 2012; **26**: 1645-1650 [PMID: 22834939 DOI: 10.1089/end.2012.0229]
93. **Hall MC**, Womack JS, Roehrborn CG, Carmody T, Sagalowsky AI. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. *J Urol* 1998; **160**: 703-706 [PMID: 9720526]
94. **Czito B**, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. *J Urol* 2004; **172**: 1271-1275 [PMID: 15371822 DOI: 10.1097/01.ju.0000137910.38441.8a]
95. **Wheat JC**, Weizer AZ, Wolf JS, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewizc P, Capitanio U, Bensalah K, Patard JJ, Shariat SF. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urol Oncol* 2012; **30**: 252-258 [PMID: 20451416 DOI: 10.1016/j.urolonc.2010.01.001]
96. **Pieras E**, Frontera G, Ruiz X, Vicens A, Ozonas M, Pizá P. Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. *BJU Int* 2010; **106**: 1319-1323 [PMID: 20394618 DOI: 10.1111/j.1464-410X.2010.09341.x]


**P-Reviewer:** Ali-El-Dein B, Creta M, Papatsoris AG, Soria F **S-Editor:** Kong JX **L-Editor: E-Editor:**




**Figure 1 Filling defect on retropyelogram, showing typical ‘goblet sign’ due to R ureteral urothelial cell carcinoma.**




**Figure 2 Central mass of upper tract urothelial cell carcinoma on left kidney, seen as renal sinus mass.**



**Figure 3 Pathologic stage of upper tract urothelial cell carcinoma.** Courtesy of third year medical student at West Virginia University, Mike Tran.



**Figure 4 Obtaining tumor specimen for pathologic stage.**



**Figure 5 Tumor resection using ureteral resectoscope with loop.**

**Table 1 TNM classification**

|  |  |
| --- | --- |
| T – primary tumor | |
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Ta | Papillary noninvasive carcinoma |
| Tis | Carcinoma *in situ* |
| T1 | Tumor invades subepithelial connective tissue |
| T2 | Tumor invades the muscularis |
| T3 | (For renal pelvis only) Tumor invades beyond muscularis into peripelvic fat or the renal parenchyma T3, (For ureter only) Tumor invades beyond muscularis into periureteric fat |
| T4 | Tumor invades adjacent organs, or through the kidney into the perinephric fat |
| N – regional lymph nodes | |
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in a single lymph node, ≤ 2 cm in greatest dimension |
| N2 | Metastasis in a single lymph node, > 2 cm but not > 5 cm in greatest dimension; or multiple lymph nodes, none > 5 cm in greatest dimension |
| N3 | Metastasis in a lymph node, > 5 cm in greatest dimension |
| M – distant metastasis | |
| M0 | No distant metastasis |
| M1 | Distant metastasis |

NCCN Guidelines® version 2, 2015[19]. Upper GU tract tumors.

**Table 2 Adjuvant treatment for renal pelvis and urothelial carcinoma of ureter**

|  |  |  |
| --- | --- | --- |
| **Pathologic staging** | **Adjuvant treatment** | **Follow-up** |
| pT0, pT1 | None | Cystoscopy every 3 mo for 1 yr, then at increasing intervals  Imaging of upper tract collecting system at 3- to 12-mo intervals, if endoscopic resection  +/- CT scan or MRI  +/- Chest x-ray |
| pT2, pT3  pT4, pN+ | Consider adjuvant  chemotherapy | Cystoscopy every 3 mo for 1 yr, then at increasing intervals  Imaging of upper tract collecting system at 3- to 12-mo intervals  +/- CT scan or MRI  +/- Chest X-ray |
| NCCN Guidelines® version 2, 2015[19]. Upper GU tract tumors. | | | |